Year Founded
2016
Ownership
Public
Employees
~10
Therapeutic Areas
Oncology
Stage
Phase 1
Modalities
Small molecule

Dracen Pharmaceuticals General Information

Lead candidate sirpiglenastat (DRP-104) in Phase 1/2 trials for solid tumors, showing promising preclinical results in combination with checkpoint inhibitors

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

sirpiglenastat
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Dracen Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Merck, AstraZeneca

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Dracen Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Later Stage VCAug 10, 2023$2.3MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Dracen Pharmaceuticals's complete valuation and funding history, request access »

Dracen Pharmaceuticals Investors

Deerfield Management
Investor Type: Venture Capital
Holding: Minority
Osage University Partners
Investor Type: Venture Capital
Holding: Minority
i&i Prague
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »